Last reviewed · How we verify

hyaluronic Acid + platelet-rich plasma

University of Milan · FDA-approved active Small molecule

Hyaluronic acid and platelet-rich plasma work synergistically to promote tissue regeneration and reduce inflammation through growth factor delivery and extracellular matrix support.

Hyaluronic acid and platelet-rich plasma work synergistically to promote tissue regeneration and reduce inflammation through growth factor delivery and extracellular matrix support. Used for Osteoarthritis (joint cartilage degeneration), Soft tissue injuries and wound healing.

At a glance

Generic namehyaluronic Acid + platelet-rich plasma
Also known asCellular Matrix/A-CP HA Kit
SponsorUniversity of Milan
Drug classRegenerative medicine / Biologic combination
ModalitySmall molecule
Therapeutic areaOrthopedics / Regenerative Medicine
PhaseFDA-approved

Mechanism of action

Hyaluronic acid serves as a biocompatible scaffold that retains moisture and facilitates cell migration and proliferation. Platelet-rich plasma delivers concentrated growth factors (PDGF, VEGF, FGF, TGF-β) that stimulate tissue repair, angiogenesis, and collagen synthesis. Together, they create an optimal microenvironment for regenerative healing in damaged tissues.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: